Petr Muller

List of Publications by Year
in descending order

59 papers	1,490 citations	361413 20 h-index	330143 37 g-index
66 all docs	66 docs citations	66 times ranked	2641 citing authors

#	Article	IF	Citations
1	C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene, 2013, 32, 3101-3110.	5.9	171
2	Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene, 2008, 27, 3371-3383.	5.9	164
3	Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. Journal of Pathology, 2005, 207, 251-259.	4.5	128
4	The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene, 2010, 29, 4838-4847.	5.9	87
5	Hsp90 Is Essential for Restoring Cellular Functions of Temperature-sensitive p53 Mutant Protein but Not for Stabilization and Activation of Wild-type p53. Journal of Biological Chemistry, 2005, 280, 6682-6691.	3.4	54
6	Docking-dependent Ubiquitination of the Interferon Regulatory Factor-1 Tumor Suppressor Protein by the Ubiquitin Ligase CHIP. Journal of Biological Chemistry, 2011, 286, 607-619.	3.4	52
7	Antiproliferative activity of olomoucine II, a novel 2,6,9-trisubstituted purine cyclin-dependent kinase inhibitor. Cellular and Molecular Life Sciences, 2005, 62, 1763-1771.	5.4	50
8	AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10â€mediated regulatory pathway. Molecular Oncology, 2016, 10, 652-662.	4.6	43
9	The Assembly and Intermolecular Properties of the Hsp70-Tomm34-Hsp90 Molecular Chaperone Complex. Journal of Biological Chemistry, 2014, 289, 9887-9901.	3.4	42
10	Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer. Cellular and Molecular Biology Letters, 2012, 17, 446-58.	7.0	41
11	Multicenter analysis of soluble <scp>A</scp>xl reveals diagnostic value for very early stage hepatocellular carcinoma. International Journal of Cancer, 2015, 137, 385-394.	5.1	41
12	Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets. Bioinformatics, 2016, 32, 9-16.	4.1	35
13	Human Stress-inducible Hsp70 Has a High Propensity to Form ATP-dependent Antiparallel Dimers That Are Differentially Regulated by Cochaperone Binding*. Molecular and Cellular Proteomics, 2019, 18, 320-337.	3.8	35
14	The Development of a Recombinant scFv Monoclonal Antibody Targeting Canine CD20 for Use in Comparative Medicine. PLoS ONE, 2016, 11, e0148366.	2.5	33
15	IFI16 Preferentially Binds to DNA with Quadruplex Structure and Enhances DNA Quadruplex Formation. PLoS ONE, 2016, 11, e0157156.	2.5	30
16	Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 415-425.	2.8	29
17	<i>MDM2</i>SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk. Oncology, 2008, 74, 84-87.	1.9	27
18	Magnetic poly(glycidyl methacrylate) microspheres for protein capture. New Biotechnology, 2014, 31, 482-491.	4.4	27

#	Article	IF	Citations
19	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Biochemical and Biophysical Research Communications, 2006, 351, 499-506.	2.1	26
20	The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer, 2010, 9, 147.	19.2	26
21	Î”Np63 regulates cell proliferation, differentiation, adhesion, and migration in the BL2 subtype of basal-like breast cancer. Tumor Biology, 2016, 37, 10133-10140.	1.8	21
22	CRISPR-Cas9 as a Tool in Cancer Therapy. Klinicka Onkologie, 2019, 32, 13-18.	0.3	21
23	Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Journal of Pathology, 2014, 233, 238-246.	4.5	20
24	Novel Entropically Driven Conformation-specific Interactions with Tomm34 Protein Modulate Hsp70 Protein Folding and ATPase Activities. Molecular and Cellular Proteomics, 2016, 15, 1710-1727.	3.8	19
25	Development of a fluorescent monoclonal antibodyâ€based assay to measure the allosteric effects of synthetic peptides on selfâ€oligomerization of AGR2 protein. Protein Science, 2013, 22, 1266-1278.	7.6	18
26	p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction. Protein Science, 2018, 27, 976-986.	7.6	17
27	The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Investigational New Drugs, 2010, 28, 445-453.	2.6	15
28	Proteinâ€“Protein Interactions Modulate the Docking-Dependent E3-Ubiquitin Ligase Activity of Carboxy-Terminus of Hsc70-Interacting Protein (CHIP)*. Molecular and Cellular Proteomics, 2015, 14, 2973-2987.	3.8	15
29	The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. Cellular and Molecular Biology Letters, 2020, 25, 41.	7.0	14
30	The cell type-specific effect of TAp73 isoforms on the cell cycle and apoptosis. Cellular and Molecular Biology Letters, 2008, 13, 404-20.	7.0	12
31	Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage. Journal of Ovarian Research, 2019, 12, 30.	3.0	12
32	The interaction of the mitochondrial protein importer TOMM34 with HSP70 is regulated by TOMM34 phosphorylation and binding to 14-3-3 adaptors. Journal of Biological Chemistry, 2020, 295, 8928-8944.	3.4	12
33	Discovery of a novel ligand that modulates the proteinâ€“protein interactions of the AAA+ superfamily oncoprotein reptin. Chemical Science, 2015, 6, 3109-3116.	7.4	11
34	MDM2â€™s dual mRNA binding domains co-ordinate its oncogenic and tumour suppressor activities. Nucleic Acids Research, 2020, 48, 6775-6787.	14.5	11
35	Impairment of carbonic anhydrase IX ectodomain cleavage reinforces tumorigenic and metastatic phenotype of cancer cells. British Journal of Cancer, 2020, 122, 1590-1603.	6.4	11
36	Inhibition of Post-Transcriptional RNA Processing by CDK Inhibitors and Its Implication in Anti-Viral Therapy. PLoS ONE, 2014, 9, e89228.	2.5	11

#	Article	IF	Citations
37	N-Truncated AÎ²2-X Starting with Position Two in Sporadic Alzheimerâ€™s Disease Cases and Two Alzheimer Mouse Models. Journal of Alzheimer's Disease, 2015, 49, 101-110.	2.6	9
38	Pull-down Assay on Streptavidin Beads and Surface Plasmon Resonance Chips for SWATH-MS-based Interactomics. Cancer Genomics and Proteomics, 2018, 15, 395-404.	2.0	9
39	Phosphomimetic Mutation of the N-Terminal Lid of MDM2 Enhances the Polyubiquitination of p53 through Stimulation of E2-Ubiquitin Thioester Hydrolysis. Journal of Molecular Biology, 2015, 427, 1728-1747.	4.2	8
40	Evidence for allosteric effects on p53 oligomerization induced by phosphorylation. Protein Science, 2018, 27, 523-530.	7.6	7
41	Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition. PLoS ONE, 2018, 13, e0202758.	2.5	7
42	Proteomics Identification and Validation of Desmocollinâ€1 and Catecholâ€Oâ€Methyltransferase as Proteins Associated with Breast Cancer Cell Migration and Metastasis. Proteomics, 2019, 19, 1900073.	2.2	7
43	A Cyclic Pentamethinium Salt Induces Cancer Cell Cytotoxicity through Mitochondrial Disintegration and Metabolic Collapse. International Journal of Molecular Sciences, 2019, 20, 4208.	4.1	7
44	A Single Conserved Amino Acid Residue as a Critical Context-Specific Determinant of the Differential Ability of Mdm2 and MdmX RING Domains to Dimerize. Frontiers in Physiology, 2019, 10, 390.	2.8	7
45	An Ultrasensitive Biosensor for Detection of Femtogram Levels of the Cancer Antigen AGR2 Using Monoclonal Antibody Modified Screen-Printed Gold Electrodes. Biosensors, 2021, 11, 184.	4.7	7
46	HSPA1A conformational mutants reveal a conserved structural unit in Hsp70 proteins. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129458.	2.4	6
47	Microthermal-induced subcellular-targeted protein damage in cells on plasmonic nanosilver-modified surfaces evokes a two-phase HSP-p97/VCP response. Nature Communications, 2021, 12, 713.	12.8	6
48	The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129722.	2.4	4
49	Anticancer pentamethinium salt is a potent photosensitizer inducing mitochondrial disintegration and apoptosis upon red light illumination. Journal of Photochemistry and Photobiology B: Biology, 2020, 209, 111939.	3.8	4
50	The Role of HSP70 in Cancer and its Exploitation as a Therapeutic Target. Klinicka Onkologie, 2018, 31, 46-54.	0.3	4
51	P0346 : Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. Journal of Hepatology, 2015, 62, S440.	3.7	3
52	An inter-subunit protein-peptide interface that stabilizes the specific activity and oligomerization of the AAA+ chaperone Reptin. Journal of Proteomics, 2019, 199, 89-101.	2.4	3
53	Hydrogen deuterium exchange mass spectrometry identifies the dominant paratope in CD20 antigen binding to the NCD1.2 monoclonal antibody. Biochemical Journal, 2021, 478, 99-120.	3.7	3
54	Rituximab induces rapid blood repopulation by CLL cells mediated through their release from immune niches and complement exhaustion. Leukemia Research, 2021, 111, 106684.	0.8	1

#	Article	IF	Citations
55	The Role of HSF1 Protein in Malignant Transformation. Klinicka Onkologie, 2018, 31, 55-62.	0.3	1
56	Abstract P1-03-07: Differential Effect of Specific p53 Mutations on Breast Cancer Growth and Response to Hsp90 Inhibition In Vivo. , 2010, , .		0
57	Mechanisms of Protein Homeostasis Regulation in Cancer Development. Klinicka Onkologie, 2016, 29, 4S18-4S24.	0.3	0
58	Impact of HSP90 Inhibition on Viability and Cell Cycle in Relation to p53 Status. Klinicka Onkologie, 2016, 29, 4S40-4S45.	0.3	0
59	Molecular Mechanisms of Carcinogenesis of Epithelial Ovarian Cancers. Klinicka Onkologie, 2016, 29, 4S46-4S53.	0.3	0